Prof. Dr. Michael Untch is a highly experienced German specialist in gynecology, breast cancer and gynecologic oncology based at Helios Klinikum Berlin-Buch. His current role includes leadership of the study center within the certified breast center and certified gynecologic oncology center, as well as a professorship in gynecology and obstetrics at Medical School Berlin.

Untch began his medical education at Ludwig-Maximilians-Universität München in 1978 and completed his medical state examination in 1985. After research work in the oncology laboratory of the University Women's Clinic Munich-Großhadern, he entered clinical training in gynecology and obstetrics. His subsequent career included a fellowship at the University of Miami's Division of Gynecologic Oncology, specialist certification in 1992 and senior academic responsibilities at LMU Munich.

His major clinical and scientific interests include breast cancer and gynecologic tumors, particularly the development and implementation of modern systemic and neoadjuvant treatment approaches. He has been involved in studies that helped influence treatment strategies for aggressive breast cancer subtypes, including HER2-positive and triple-negative disease.

Breast cancer treatment is increasingly individualized. Treatment decisions can involve surgery, chemotherapy, endocrine therapy, targeted treatment, immunotherapy and radiation therapy. The most appropriate combination depends on tumor biology, stage, hormone receptor status, HER2 status, genetic findings, lymph-node involvement and the patient's overall health.

Neoadjuvant treatment is given before surgery and can be used in selected breast cancer cases to reduce tumor burden, assess treatment response and facilitate subsequent surgical management. It can be particularly relevant for certain aggressive or locally advanced breast cancers.

Untch's work has contributed to research involving neoadjuvant approaches in HER2-positive and triple-negative breast cancer. His current institutional profile notes that research from his clinical environment has helped shape treatment approaches for aggressive breast cancer forms and has been published internationally.

The certified Breast Center at Helios Berlin-Buch provides an interdisciplinary approach to breast cancer management. Its services bring together diagnostic imaging, surgery, pathology, radiation oncology, oncology, psycho-oncology and other disciplines.

Such multidisciplinary care is important because breast cancer treatment rarely involves one medical specialty alone. A patient may initially undergo mammography, ultrasound or breast MRI, followed by biopsy and pathological analysis. The resulting information is then used to determine the appropriate treatment pathway.

Gynecologic oncology is another major area of Untch's expertise. This includes the diagnosis and management of cancers affecting the ovary, uterus and external genital organs, as well as precancerous conditions. Treatment can involve surgery, systemic medication, radiation therapy and coordinated specialist follow-up.

Clinical research is a further component of his work. Helios Berlin-Buch reports participation in national and international Phase II, III and IV studies investigating new treatment strategies for breast and gynecologic cancers, including antibody-based and targeted therapies.

For international patients, a consultation with a breast cancer specialist may be particularly useful when a diagnosis is complex, when a second opinion is required, or when patients want to understand whether newer treatment approaches are appropriate. Medical records should ideally include biopsy results, pathology reports, imaging, previous treatment details and current medications.

With approximately four decades of clinical and academic experience, Prof. Dr. Michael Untch is a strong featured specialist for patients researching breast cancer and gynecologic oncology treatment in Germany. His combination of clinical leadership, research involvement and specialist cancer expertise makes him particularly relevant for complex women's cancer care.